Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
March 19, 2024
Earnings Call Speaker Segments
Zack Kubow
executiveThanks, operator, and good afternoon to all of you. We appreciate you being with us for Corvus Pharmaceuticals' conference call covering the Fourth Quarter and Full Year 2023 Business Update and Financial Results; here to talk through the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, our Chief Financial Officer; Jeff Arcara, our Chief Business Officer; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Some prepared remarks from the executive team will kick off the call, and a question-and-answer period will follow. A reminder to everyone that forward-looking statements will be part of what management says today and in the answers to questions. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' annual report on Form 10-K, filed today with the SEC, as well as other filings the company makes with the SEC from time to time. Except as required by law, the company assumes no obligation to publicly update or revise any forward-looking statements. With that, I'd like to turn the call over to Leiv Lea. Leiv?
Leiv Lea
executiveThanks, Zack. I'll kick things off with a brief look at how we did in the fourth quarter and across all of 2023, and after that I'll hand things to Richard for an update on the business. Spending on research and development came to $4 million during Q4 of 2023, versus $4.1 million in the comparable stretch of 2022. For all of 2023, R&D costs reached $16.5 million, down from $24.5 million across the whole of 2022. We posted a net loss of $6.7 million in the fourth quarter of 2023, which took in a $1.4 million noncash loss tied to Angel Pharmaceuticals, our partner based in China. That stacks up against a net loss of $9.8 million in the same quarter of 2022, a figure that had incorporated a $4.6 million noncash loss connected to Angel Pharmaceuticals. Our net loss across all of 2023 came to $27 million, with $5.3 million of that being a noncash loss linked to Angel, whereas the comparable net loss for the whole of 2022 was $41.3 million, which had included a $10 million noncash loss tied to Angel. Total stock compensation expense for Q4 and for the entire year of 2023 came in at $0.6 million and $2.1 million, respectively, against $0.6 million and $2.7 million during the equivalent period of 2022. At the close of December 31, 2023, Corvus held cash, cash equivalents and marketable securities amounting to $27.1 million, compared with $42.3 million as of December 31, 2022. At this point I'll pass the call to Richard, who will walk through our clinical progress and go into more detail on our strategy and plans.
Richard Miller
executiveThanks, Leiv, and hello to everyone this afternoon. We appreciate you taking the time to join today's call about our business update. Corvus has emerged as a trailblazer in researching and developing ITK inhibition as a novel therapeutic approach that could help patients across a wide variety of diseases. We've shown that blocking this target selectively produces meaningful biologic activity that may translate into new options for treating cancer and immune-related conditions. During 2024, our attention is on 2 main value drivers to further validate and move this opportunity forward: number one, opening patient enrollment for a registrational Phase III study of soquelitinib in individuals with relapsed PTCL, or peripheral T cell lymphomas — a condition where no therapies have full FDA approval and where unmet need remains substantial; and number two, opening patient enrollment for a placebo-controlled Phase I study of soquelitinib in people with moderate to severe atopic dermatitis, which should yield the initial clinical results for ITK inhibition in an immune disease before this year ends. We feel Corvus is set up to create near-term value through important upcoming clinical milestones for soquelitinib in oncology and immune diseases, which further bolsters our continuing business development efforts, focused on partnership opportunities around ITK inhibition. Data published recently showed the possible role of ITK across a wide array of indications, and we've grown our capabilities and our approach to business development by naming Jeff Arcara as Chief Business Officer. Jeff is going to share his perspective and strategy shortly. Now I'll give more detail on our 2 priorities for this year along with our other programs, beginning with soquelitinib for PTCL. Our plan is to open patient enrollment for the soquelitinib registrational Phase III clinical study in relapsed PTCL during the third quarter of 2024. Results from our Phase I study keep developing as we follow treated patients longer. At the latest data cutoff from January 2024, we observed that a patient whose partial response had been reported earlier — roughly 80% target lesion reduction following 9 weeks of treatment — later became a complete response at 18 weeks because the tumor kept responding; this patient, still receiving therapy, had relapsed extranodal NK/T-cell lymphoma involving the nasopharynx, and is the fourth complete response among 21 Phase III eligible patients in the study. The objective response rate, or ORR, for Phase III eligible patients in the Phase I study holds at 7 out of 21 patients, with 4 CRs and 3 PRs, or 33%. Though no head-to-head comparison was performed, the ORR, complete response rate, disease control rate, progression-free survival and overall survival for this group stack up well against what's been seen with belinostat or pralatrexate — the standard chemotherapies for PTCL that we'll be comparing against in a Phase III study; those agents won accelerated approval in the United States, yet no definitive trial has ever been run for either. For our patients, the median PFS — that's progression-free survival — and the primary endpoint of our Phase III trial is still 6.2 months, a figure that's considerably superior to what's been reported with the standard agents. As for how things stand with FDA, we came to agreement on the final version of the study protocol, and back in February they awarded soquelitinib orphan drug designation for treating T cell lymphomas. That's a significant milestone, and it underscores how much unmet need exists for these patients, since the drugs available today deliver only limited efficacy and come with notable toxicity. Indeed, the current NCCN guidelines for relapsed/refractory PTCL call for patients to enroll in an experimental clinical trial as the preferred option in the second-line setting. We're either already collaborating with or are far along in talks with many top centers across the United States and Canada. We expect roughly 40 centers to take part in the trial. The great majority of those will be in the U.S. Our number two priority is soquelitinib in atopic dermatitis, which is the first immune disease indication we're pursuing. Our intention to launch a clinical trial is backed by our preclinical research, among it the successful use of soquelitinib to treat spontaneous canine atopic dermatitis. We remain on schedule to begin a Phase I trial in April; the plan is to enroll 64 patients who have moderate to severe atopic dermatitis that has progressed on at least one prior therapy. This study is randomized, placebo-controlled, and blinded to the patients as well as the treating physician. It will comprise 4 sequentially enrolled cohorts of 16 patients, and within every cohort patients get randomized 3:1 to various dosing regimens of soquelitinib or placebo given over 28 days. Safety and tolerability make up the primary endpoint, while efficacy will be assessed through investigator global assessment and through the clinically validated measurement of improvement in Eczema Area and Severity Index, or EASI, E-A-S-I. Worth noting: although the atopic dermatitis trial is double-blind — the patient and the doctor are blinded — the company itself is not blinded. We intend to review the data continuously as each successive cohort of patients finishes enrollment. Given the expected enrollment and follow-up time lines, we believe data from the initial cohorts should be in hand before the end of 2024, with the study finishing in early 2025. We're planning a solid tumor trial in relapsed renal cell cancer, though we're giving priority to getting the PTCL and atopic dermatitis trials started. Our intention to launch a clinical trial is backed by our preclinical research along with independent academic confirmation from a team at Erasmus University in Rotterdam. The plan is to run the trial in partnership with investigators at the Kidney Cancer Research Consortium. The clinical and preclinical results we've observed with soquelitinib have driven us to look for additional analogs of ITK inhibitors. Back in February, we shared data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases. That presentation featured the initial characterization of our next-gen ITK inhibitors, compounds built to provide accurate T cell modulation tuned for particular immunology indications. Because ITK inhibition holds such wide-ranging promise across inflammatory and immune-mediated conditions, we're looking to partner with biotech or pharma organizations whose proven development and commercialization strengths align with these different opportunities. To speed up our business development work, we brought on Jeff Arcara as Chief Business Officer during February. He comes to Corvus with over 30 years of commercial experience in biopharma, including wide-ranging functional expertise spanning commercial development, corporate development, product licensing and partnering, and corporate strategy. I'll hand the call over to Jeff now so he can offer a few brief comments on our business development efforts. Jeff?
Jeff Arcara
executiveThanks, Richard, and good afternoon to all of you. It's a real thrill for me to become part of the Corvus team and help move forward a pipeline that holds a great deal of promise. When it comes to cancer, Corvus concentrates on spaces where needs remain largely unmet, pursuing a novel target that also carries meaningful commercial potential. What drew me to Corvus right now was how compelling the opportunity looked, given the various possible milestones and crucial inflection points lying ahead for the company across the coming 6 to 12 months, among them the launch of our Phase III trial, soquelitinib for relapsed PTCL, which tackles an indication where needs are significantly unmet and offers the chance to deliver an important new treatment choice to patients while building value for Corvus. Looking at it commercially, should it win approval, it would stand as the sole fully FDA-approved therapy for relapsed PTCL. To grasp how large this opportunity is, think about the following points. PTCL carries a very substantial unmet need, with survival over 5 years sitting at a very low rate below 20%, meaning new and effective therapies are desperately needed; an estimated 70,000 PTCL cases exist worldwide, while current U.S. treatment pricing runs from $200,000 all the way to $600,000 annually. Soquelitinib offers a near-term commercial opening, with our planned Phase III trial protocol set to enroll 150 patients. The market for hematologic malignancy drugs is sizable, at roughly $55 billion, and is expected to reach $90 billion by 2028. As a benchmarking exercise, ADCETRIS, an anti-CD30 drug conjugate, posted global sales of $1.6 billion in 2023, with roughly $558 million of that estimated to come from non-Hodgkin's lymphoma patients, mainly those with anaplastic T cell lymphoma, a PTCL subset representing about 15% to 20% of cases. Taken together, these elements make the PTCL opportunity considerable for a novel effective treatment, much as has been observed with other disease-modifying therapies in hematology. Looking more broadly, we see PTCL as an entry point, with many possible routes to broaden the opportunity and assist more patients facing solid tumors and immune diseases. In light of all this, we believe soquelitinib and our next-generation ITK inhibitors could prove an appealing opportunity for partners, thanks to the unique mechanism of action, the human safety data on soquelitinib from our Phase I lymphoma trial, the large and diverse market opportunities across oncology and immunology, and our strong intellectual property position, with issued composition of matter patents for soquelitinib running through November 2037, not counting likely extensions. Given that, our preferred partnering strategy involves finding partners with development and commercialization expertise in immune disease, along with pursuing regional partnerships in oncology. Partnering interest has gained increasing momentum since we announced our Phase III registration trial in the third quarter of 2023, alongside recent publications on soquelitinib's activity and preclinical models of cancer and immune diseases. I'll now hand the call back over to Richard.
Richard Miller
executiveThanks, Jeff. Now, regarding the programs we run with partners: the Kidney Cancer Research Consortium is in the process of signing up patients for the Phase II component of the Phase Ib/II study that is testing ciforadenant, an adenosine A2A receptor inhibitor, as a possible first-line treatment for metastatic renal cell cancer given alongside ipilimumab and nivolumab. Enrollment for this trial is planned to reach as many as 60 patients, and roughly 25 have joined so far. Given where the time lines stand now, we expect the first interim data during the first half of 2024. What's encouraging is that as more patients come in, we keep observing that the deep response rate is above our 32% benchmark, which is based on 14 evaluable patients who have had at least one follow-up assessment — that's up from 8 evaluable patients when we held our Q3 call. As a reminder, deep response rate means complete response plus partial responses that go beyond 50% tumor volume reduction. Others have demonstrated that this endpoint predicts prolonged progression-free survival, and with ipilimumab and nivolumab it stands at 32%; as for mupadolimab, our anti-CD73 antibody, our partner Angel Pharmaceuticals keeps enrolling patients in a Phase I/Ib clinical trial being run in China, using mupadolimab by itself and in combination with pembrolizumab in patients who have non-small cell lung cancer and head and neck squamous cell cancers. To sum up what 2024 looks like, the cash we currently hold lets us reach near-term milestones, among them launching our registrational Phase III clinical trial of soquelitinib in PTCL, producing interim data from the early cohorts of the soquelitinib Phase I atopic dermatitis clinical trial, and reporting interim data for ciforadenant in renal cell cancer during the first half of 2024. We intend to use these near-term milestones and achievements as we pursue additional funding and partnerships for our ITK inhibitors in immunology and oncology, along with our other novel programs, such as the A2A receptor antagonist ciforadenant. We're eager to share updates on our programs over the next few quarters. At this point I'll hand the call to the operator for a question-and-answer period. Operator?
Jiayuan Gong
analystJerry here, filling in for Graig. We might have 2 questions. First, regarding the launch of the Phase III soquelitinib study, could you describe what is holding up the beginning of that trial? Also, has the protocol been modified at all since then? I have another question after this.
Richard Miller
executiveNo modifications or adjustments have been made to the protocol. Regarding the trial's design statistics and other parameters, we have been fully aligned with FDA. In that respect, nothing has been altered. As our follow-up gets longer, our Phase I data keeps getting better; right now we are finalizing agreements with the different sites, and honestly there are no gating items besides the typical administrative matters.
Jiayuan Gong
analystUnderstood. That's really useful. Then I have something to ask you, Jeff. You mentioned a pricing range for PTCL. Could you expand a bit on how Corvus views its own position within that range, or within that spectrum of scaled pricing?
Jeff Arcara
executiveSure. Thank you. When it comes to pricing, clearly we examine analogs and what the market currently charges across these segments. I believe you factor in how large the patient population is that you're targeting; however, what matters more is that pricing will largely be driven by how big the unmet medical need is, which we know is quite substantial in PTCL, along with the product profile we bring forward, meaning the safety and efficacy data in our possession; so clearly, we're reviewing analogs right now. Yet in the end, the price gets determined after we obtain the final data and conduct some payer testing around the value proposition.
Jeff Jones
analystI suppose that makes 2 for me. With the extra CR that's now in the PTCL study, could you address the confirmed against unconfirmed reported outcomes? And to be clear, what number of those fall into confirmed versus unconfirmed? Then I have one follow-up.
Richard Miller
executiveEvery one of them is confirmed. All confirmed. Right. Also, Jeff, I'd mention that typically with relapsed disease, we don't — the majority of clinicians don't actually discuss confirmed and unconfirmed; that fits better in frontline therapy. When it's relapsed disease, particularly in this disease, patients survive for such a brief period that in half your case, it's hard to even keep people going past a few months. So — yet every response we have is confirmed, partial and complete.
Jeff Jones
analystLooking at that swimmer plot you've presented, it seems a number of patients are still at a fairly early stage of treatment; it gives the impression that enrollment might still be ongoing for that trial; so, are patients still being enrolled in that Phase I study? And could you potentially move those patients into the Phase III?
Richard Miller
executiveNo new patients are being enrolled in the Phase I study. Those individuals displayed on the swimmers and waterfalls, several of whom remain on therapy, will of course be followed and kept on treatment until disease progression occurs; however, no additional patients are entering the Phase I; our centers are now the focus — a lot of the sites that took part in the Phase I are also taking part in the Phase III; so those people are now concentrated on the Phase III trial.
Liang Cheng
analystLiang Cheng here, filling in for Roger. We've got 2 questions, I believe. The first one concerns soquelitinib and the updated Phase I data. Regarding the 5 patients who saw tumor reductions but didn't meet PR criteria — what was the duration of their treatment? And for the 2 who are still on it, how long have they been receiving treatment? I have a follow-up after that.
Richard Miller
executiveRight — for the ones who haven't — okay, so your first question was about those not yet meeting PR criteria, and how many remain — how long they're still receiving treatment. If you check the swimmer plot, which you can review on your own, by the way, one is 5 months. One is roughly 6 months, another is 7 or 8 months, okay? The rest have been PRs. That's my quick read of the swimmer. And what was the second part of your question?
Liang Cheng
analystRegarding the 2, do they stay on the therapy? So yeah, I suppose...
Richard Miller
executiveThey remain on the therapy. Individuals keep receiving treatment up until they progress or encounter some kind of safety problem, though that has not occurred.
Liang Cheng
analystAll right, so let's perhaps shift to the next topic...
Richard Miller
executiveDoes that make sense?
Liang Cheng
analystYes, yes. My second question concerns the Phase I trial in atopic dermatitis. Patients need to have failed at least one earlier treatment — are there any particular criteria around that?
Richard Miller
executiveI didn't catch the last part of what you said — patients must have failed one previous topical or systemic therapy. They need moderate to severe atopic dermatitis. They are required to have not responded to their earlier treatment. Does that address your question?
Liang Cheng
analystYeah, yeah.
Rosemary Li
analystRosemary here, filling in for Li. First off, could you go over the benchmarks again for relapsed/refractory PTCL — what do you expect to see? There was some interference earlier on the call, so I missed that part. Then I have a follow-up question as well.
Richard Miller
executiveRight now, the standard agents for relapsed peripheral T cell lymphoma are pralatrexate and belinostat. Those drugs got accelerated approval roughly 15 years back, and the confirmatory trials were never run by the companies. As a result, no drug today holds full FDA approval for relapsed PTCL. Essentially, pralatrexate and belinostat are chemotherapy agents. Belinostat works as an HDAC inhibitor, while pralatrexate is a folate antagonist. The usual chemotherapy toxicities — neutropenia, thrombocytopenia, anemia — affect both of those drugs. An extra toxicity, mucositis, affects pralatrexate. The response — those patients — single-arm Phase II studies enrolling somewhere between 100 and 120 patients served as the basis for those drugs' approval. Roughly 25% was the response rate. For PFS, progression-free survival, with belinostat, I believe it was 1.6 months, and with pralatrexate, around 3 months, if I remember correctly. On our website, in the slide presentation, we have a slide covering this. So with ours, we see a 33% response — a 33.3% response rate, with more than half of those being CRs. Ours has a CR rate roughly double that of the 25% or so response rate seen with pralatrexate and belinostat — about 10% with CRs. Among our responders, the majority are CRs, even though the number is small. In hematology, and particularly in the lymphoma world, CRs matter greatly. In our hands, progression-free survival comes to 6.2 months, which is considerably better than the 1.6 and 3.0 months I mentioned earlier. So we — our study of — let me continue, since I think I know where we are headed, the — our study design, the statistical design, calls for enrolling 150 patients, 75 per arm, standard of care versus soquelitinib, 75 per arm, as I said. We — the power, we have roughly 89%, 90% power to detect an improvement from about 3.5 months to 5.5 months, which is our target, okay?
Rosemary Li
analystUnderstood. Yes. I appreciate how detailed that response was; now I've got a fast question regarding atopic dermatitis; as for the results we might receive later in the year, do you have any expectations about what that data will look like, such as patient numbers or dose counts? Or is it simply too soon to say?
Richard Miller
executiveNo, no, we can estimate that quite well. Okay. To begin with, we already understand a great deal about how this drug is dosed, given that we've been testing it in lymphoma patients. We have substantial knowledge regarding pharmacokinetics, target occupancy, safety, and so forth; therefore, we plan to study 4 cohorts of patients, with enrollment happening one after another. So we begin with, say, the cohort receiving the low dose, which for us means 100 milligrams BID. In our lymphoma trials and the planned Phase III, the dose is 200 milligrams BID. Thus for 100 milligrams BID, we'll bring in 16 patients under a 3:1 randomization, with 12 receiving soquelitinib and the remaining 4 getting placebo; after that we move to the following dose schedule, which is 200 milligrams once a day, since we believe once-daily administration will work and, naturally, we think it's more convenient. So the same approach: 16 patients enter that group. Once more, 3:1 randomization, 12 receive soquelitinib, 4 receive placebo. Then we proceed to the third cohort, which is 200 milligrams twice daily, the identical regimen being used in lymphoma. Same concept: 12 patients receive the drug, 4 receive placebo, again with randomization. After that, the last cohort would be 400 milligrams once daily; the rationale for examining these cohorts is that we know at 200 milligrams, you achieve full occupancy of the receptor. At 100, occupancy is fairly good, though not complete, yet likely sufficient to produce some biologic effect. So it wouldn't surprise me if we observe some effect even at the lowest dose schedule. As I said before, the physician and the patient are blinded. The company is not. That means we can examine the data, and we have a data monitoring board able to review it once each cohort has been enrolled; and we can choose to report that data or keep it unreported. I don't expect we'll be reporting it weekly. But at our discretion, we're able to report that data. Additionally, there's a substantial amount of biomarker data that will build up throughout the study. We're assessing multiple cytokines and lymphocyte subsets, and so on and so forth; and we already know from our lymphoma trials and the other animal research we've conducted and published that we understand which biomarkers and cytokines are impacted, such as IL-4 and IL-5 and others. So at every cohort, the main thing we'd be watching for is obviously safety. In our treatment arm, we'd be examining biomarker shifts compared with baseline. Comparing every patient against his or her own baseline, we'd anticipate seeing alterations in IL-4 and 5, along with all of those other measures. And naturally, physicians will be judging how well it works using the grading criteria I brought up before — the EASI score plus the investigator global assessment. So from each one of these, we're going to gain a great deal of knowledge. Regarding the dosing now — as I said, we already understand a great deal about it. That lets us begin at 100 milligrams BID. My expectation is that we'll observe something quite soon in this trial. And I believe we'll learn quickly, not just regarding efficacy, but regarding biologic activity too, since — keep in mind — the reason atopic dermatitis is our first pick is that it fits squarely what's termed a Th2, T helper cell 2 disease, one mediated by IL-4 and 5 and 13, and our drug, we know, blocks Th2 function extremely well; we found this out through our lymphoma studies and through our other studies, the preclinical ones. So quite early in the trial, we'll be able to establish things about safety. That much we already know from the lymphoma work. We'll be able to establish if the immunologic effects we anticipate are occurring and, naturally, we'll be tracking clinical efficacy. The immunologic effects matter, you see, because this serves as the entry point, the stepping stone toward other immune diseases. Which other immune diseases? Asthma is one that would be — it's strongly Th2, psoriasis, scleroderma, a number of others. There's a full list of them in our website presentation. So this trial matters a great deal, since we obtain data fast and it tells us so much, not merely for atopic dermatitis's sake, but it unlocks the entire field. Essentially, through this study, ITK inhibition gets put on the map as a significant therapeutic modality across a host of immune diseases. It brings to mind strongly an antibody I worked on called Rituxan and — where we — what lymphoma taught us regarding what happens to B cells, et cetera. And that created opportunities for many other dermatologic and immunologic diseases. So that was a lengthy way to respond to your question, but I wanted to be sure we truly had the right perspective. I appreciate the question.
Richard Miller
executiveAppreciate it, operator. So, my thanks go out to all of you for joining us on today's call; we're eager to share further updates every quarter and to keep moving soquelitinib and our other products forward over the next few months. Many thanks to all of you.
Operator
operatorThank you. This concludes today's call. All parties may disconnect. Have a good day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.